Robert Bhisitkul and Tejal Desai describe how treatment for retinal diseases leading to vision loss, such as age related macular degeneration, may be much improved by efforts to develop implantable devices for drug delivery.
Age related macular degeneration (AMD) is one of several retinal diseases that can lead to vision loss and, ultimately, blindness. Dr. Bhisitkul explains that the class of anti-VEGF biologic drugs (Lucentis, Avastin, Eylea) can treat AMD, however, ongoing, monthly injections into the eye are required for the drugs to be fully effective. There are a number of drawbacks to this treatment regime, many of which could be mitigated by the development of a drug delivery device for implantation in the eye. Dr. Desai describes the work done in her lab to develop an injectable, biocompatible and biodegradable device that has the right release kinetics to successfully deliver needed drugs to the retina of patients with AMD.
Dr. Tejal Desai is a Professor of BioEngineering and Therapeutic Sciences at the University of California, San Francisco and head of the Therapeutic Microtechnology and Nanotechnology Laboratory. Her lab strives to develop new approaches to delivering drugs to specific cells such as the retina, as well as developing materials for bioengineering. Desai did her undergraduate… Continue Reading
Dr. Robert Bhisitkul is a Professor of Clinical Ophthalmology at the University of California, San Francisco where he specializes in vitreoretinal surgery. Bhisitkul received his MD from Stanford University and his PhD in neurosciences from Yale University. Continue Reading